## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `pt-141-nerve-damage`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/pt-141-nerve-damage/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/pt-141-nerve-damage/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/pt-141-nerve-damage/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/pt-141-nerve-damage/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/pt-141-nerve-damage/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/pt-141-nerve-damage/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `pt-141-nerve-damage` v2 · content_hash `3af525767974752f…` · thread_head genesis · 22 DIVs
- **thesis (c1):** No human clinical trials test PT-141 for nerve damage or neuropathy.
  - c2 [preclinical/active] In a 2003 rat sciatic nerve crush model, Melanotan-II (MT-II) at 20 μg/kg every 48 h improved sensory recovery and showed partial neuroprotection against cispla
  - c4 [preclinical/active] A 2004 rat study found only non-selective melanocortin agonists like MT-II accelerated sensory recovery after nerve crush, unlike selective MC4 agonists.
  - c3 [mechanistic/active] PT-141 activates MC3R and MC4R centrally to influence sexual arousal pathways.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/pt-141-nerve-damage/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/pt-141-nerve-damage/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `pt-141-nerve-damage`
- **title:** PT-141 for Nerve Damage: Evidence-Graded Review
- **url:** https://miscsubjects.com/a/pt-141-nerve-damage
- **register:** source_ledger
- **updated:** 2026-07-17T02:41:08.026Z
- **tags:** peptide, matrix

## Body

## What's breaking down

Nerve damage involves layers of degeneration. Axons can break or retract after injury or toxicity. Myelin sheaths around nerves can degrade, slowing signal conduction. Schwann cells and supporting glia may fail to remyelinate or guide regrowth. Sensory and motor endpoints lose function, leading to numbness, weakness, or pain. Central nervous system components tied to arousal pathways can also show disrupted signaling if peripheral input is lost. These layers create a net where breakdown outruns natural repair, leaving persistent deficits. PT-141 is discussed here in the context of its studied effects on melanocortin pathways in the CNS that influence arousal, not as a direct nerve regenerator.

## Why PT-141 might help you

1. If your nerve damage affects sexual function through reduced CNS arousal signaling, PT-141 is studied because it activates melanocortin receptors (MC3R and MC4R) in brain areas linked to motivation and desire. 
2. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. The compound engages central pathways that may support downstream tissue responses rather than blocking symptoms.
3. If peripheral nerve issues have secondarily dampened arousal circuits, the central action could interact with remaining neural pathways. 
4. This framing stays at the sexual/CNS arousal layer; other degeneration layers require separate approaches.

## How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- **PT-141** → sexual / CNS arousal

## What the evidence actually shows

Human data: No clinical trials directly test PT-141 for nerve damage or neuropathy. Approved use is limited to hypoactive sexual desire disorder via subcutaneous injection, with phase 2/3 studies showing central effects on arousal but no nerve repair endpoints (source s15, s20).

Preclinical data: A 2003 rat study used Melanotan-II (MT-II), a closely related melanocortin agonist and precursor analog to PT-141. Rats received a sciatic nerve crush injury. MT-II at 20 μg/kg every 48 hours improved sensory recovery speed compared with controls. The same compound showed partial protection against cisplatin-induced toxic neuropathy. Effects were dose-specific; lower and higher doses were less effective. This is rat data only and does not prove effects for PT-141 itself (source s35).

A follow-up 2004 rat study compared selective MC4 agonists to non-selective MT-II in the same crush model. Only the non-selective agonist accelerated sensory recovery, suggesting broader receptor activity matters (source s36).

Anecdotal: No structured human reports tie PT-141 directly to nerve regeneration. Related compounds like MT-II appear in limited online discussion for libido effects, with one mention of the 2003 rat nerve study (source s24).

## What scientists say

Researchers describe MT-II as having neurotrophic and neuroprotective properties in rat peripheral nerve models, but emphasize these are early findings limited to animals. Human translation remains untested for nerve outcomes. PT-141 shares receptor targets but lacks dedicated nerve studies.

## What people say on Reddit

Discussions focus on PT-141 for sexual arousal rather than nerve repair. One thread notes MT-II's animal data on sciatic nerve recovery but stresses the compound difference and lack of human evidence. Users report variable libido effects with PT-141 but no claims of nerve healing.

## What people say on X

Posts about PT-141 center on on-demand arousal benefits and side effects like nausea. No prominent mentions link it to nerve damage recovery.

## What we do not know

No human trials exist for PT-141 in nerve damage. Dose, timing, and receptor selectivity differences between PT-141 and MT-II are uncompared in nerve models. Long-term effects on damaged nerves are unknown. Whether central arousal changes translate to peripheral repair remains speculative.

## Safety and limits

PT-141 is FDA-approved for HSDD with known side effects including nausea, flushing, and injection-site reactions. It carries warnings for blood pressure increases. Any off-label exploration for nerve-related issues carries the same profile plus unknown efficacy. Evidence for nerve applications is preclinical at best and does not support use.

## Claims (4)

- **c1** [human w=0.8] No human clinical trials test PT-141 for nerve damage or neuropathy.
  - who_claims: grok/grok-4.3
  - sources: s15, s20
- **c2** [preclinical w=0.5] In a 2003 rat sciatic nerve crush model, Melanotan-II (MT-II) at 20 μg/kg every 48 h improved sensory recovery and showed partial neuroprotection against cisplatin neuropathy.
  - who_claims: grok/grok-4.3
  - sources: s35
- **c3** [mechanistic w=0.3] PT-141 activates MC3R and MC4R centrally to influence sexual arousal pathways.
  - who_claims: grok/grok-4.3
  - sources: s16
- **c4** [preclinical w=0.5] A 2004 rat study found only non-selective melanocortin agonists like MT-II accelerated sensory recovery after nerve crush, unlike selective MC4 agonists.
  - who_claims: grok/grok-4.3
  - sources: s36

## Voxel graph (4 atoms · 9 edges)
- full graph: https://miscsubjects.com/api/articles/pt-141-nerve-damage/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (6)
- chain valid: yes · head: `091fe30de88bbb61`

### s15 · pubmed · ok
- title: Double-blind, placebo-controlled evaluation of the safety, pharmacokinetics and pharmacodynamics of PT-141
- url: https://pubmed.ncbi.nlm.nih.gov/14963471/
- summary: Phase 1/2 safety data for PT-141 in humans; no nerve endpoints.
- quote: PT-141 was safely administered and well tolerated in both studies.
- claim_ids: c1
- hash: `979ad7a8f971dbf7`

### s16 · pubmed · ok
- title: Melanocortin Receptors, Melanotropic Peptides and Penile Erection
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC2694735/
- summary: Review of PT-141 mechanism via melanocortin receptors.
- quote: PT-141 (Bremelanotide®) is currently the most studied melanocortinergic compound with regard to therapeutic potential for treatment of erectile dysfunction.
- claim_ids: c3
- hash: `69ec7a0c91e64467`

### s20 · other · ok
- title: Other Review(s) - FDA NDA for Bremelanotide
- url: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000OtherR.pdf
- summary: FDA review confirming approved indications and trial scope.
- quote: Approximately 3500 patients have been treated with Bremelanotide in 43 clinical studies involving indications of erectile dysfunction, and HSDD.
- claim_ids: c1
- hash: `8361c9c1eee5066e`

### s35 · pubmed · ok
- title: The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat
- url: https://pubmed.ncbi.nlm.nih.gov/12591111/
- summary: Key rat study on MT-II in nerve crush and toxic neuropathy models.
- quote: Melanotan-II significantly enhanced the recovery of sensory function following a crush lesion of the sciatic nerve in the rat at a dose of 20 microg kg(-1) per 48 h, s.c.
- claim_ids: c2
- hash: `97096ff87faa79af`

### s36 · pubmed · ok
- title: Accelerating sensory recovery after sciatic nerve crush: non-selective versus melanocortin MC4 receptor-selective peptides
- url: https://pubmed.ncbi.nlm.nih.gov/15249163/
- summary: Follow-up rat study comparing selectivity.
- quote: Both peptides did not accelerate sensory recovery in rats with a sciatic nerve crush, whereas the non-selective melanocortin agonist melanotan-II (MTII...) was effective.
- claim_ids: c4
- hash: `3b589ec2ec8a8bae`

### s24 · reddit · ok
- title: PT-141 vs Melanotan-2
- url: https://www.reddit.com/r/BodyHackGuide/comments/1p4o2lm/pt141_vs_melanotan2_which_one_boosts_sex_drive/
- summary: Community mention of the 2003 rat study in context of related compound.
- quote: MT2 promoted nerve regeneration in sciatic nerve injury
- hash: `091fe30de88bbb61`

## Provenance (2 model passes)
- chain valid: yes · head: `07a95d0b8b6edaaa`

- write · grok/grok-4.3 · 2026-06-30T01:13 · hash `60ed75dd318e`
- voxel_divide · owner · 2026-07-17T02:41 · hash `07a95d0b8b6e`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/pt-141-nerve-damage/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/pt-141-nerve-damage/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"pt-141-nerve-damage","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest pt-141-nerve-damage|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim pt-141-nerve-damage|tier|assertion`
- **iMessage ask:** `pt-141-nerve-damage|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `pt-141-nerve-damage`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/pt-141-nerve-damage/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/pt-141-nerve-damage/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*